26818-07-5

Basic information

• Product Name: 2-Hexanone, 1-bromo-
• Synonyms: Brommethyl-butyl-keton;1-bromo-2-hexanone;1-bromohexan-2-one;1-bromo-hexan-2-one;1-bromohexanone;1-Brom-hexan-2-on
• CAS NO: 26818-07-5
• Molecular Formula: C6H11BrO
• Molecular Weight: 179.057
• Mol File: 26818-07-5.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 86-88 °C
• Density: 1.284 g/cm3(Temp: 30 °C)
• CAS DataBase Reference: 2-Hexanone, 1-bromo-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hexanone, 1-bromo-(26818-07-5)
• EPA Substance Registry System: 2-Hexanone, 1-bromo-(26818-07-5)

Safety Data

• Hazardous Substances Data: 26818-07-5(Hazardous Substances Data)

Upstream product

• 591-78-6 n-hexan-2-one 
• 3017-66-1 2-bromohex-1-ene 
• 13154-12-6 1-bromohexene 
• 186581-53-3 diazomethane 
• 638-29-9 n-valeryl chloride 
• 592-41-6 1-hexene 
• 626-93-7 n-hexan-2-ol 
• 109-52-4 valeric acid 
• 67-66-3 chloroform 
• 408517-55-5 chloro-acetic acid-(1-butyl-vinyl ester) 
• 7726-95-6 bromine 
• 109-72-8 n-butyllithium 
• 105-36-2 ethyl bromoacetate 
• 75-91-2 tert.-butylhydroperoxide 

Downstream Products

• 41693-11-2 1-(triphenylphosphoranylidene)-2-hexanone 
• 1421863-28-6 C₃₂H₃₆N₂O₄S₂ 
• 1421863-27-5 C₂₈H₂₈N₂O₄S₂ 
• 1421863-26-4 C₅₀H₄₆N₄S₂ 
• 138459-20-8 methyl 4'-<(2-butylimidazo<1,2-a>pyridin-3-yl)methyl>biphenyl-2-carboxylate 
• 138459-13-9 4'-(2-Butyl-imidazo[1,2-a]pyridin-3-ylmethyl)-biphenyl-2-carboxylic acid 
• 371-91-5 2,2-difluoro-hexane 
• 114432-26-7 2-n-Butyl-1-(4-tosyloxybenzenesulphonyl)indolizine 
• 154695-46-2 C₂₃H₂₈N₂O₅ 
• 53181-04-7 2-amino-4-n-butyl-thiazole 

Relevant articles and documents

Oxymetallation. Part 14. Modified Procedures for t-Butyl Peroxymercuriation and Bromodemercuriation that Lead to an Improved, Stereoselective, Conversion of Non-terminal Alkenes into β-Bromoalkyl

Stereospecific trans-peroxymercuriation of non-terminal alkenes with little or no accompanying acyloxymercuriation has been accomplished by using mercury(II) acetate under conditions of equilibrium control induced by the presence of 20 molpercent of perch

Using Small-Molecule Adjuvants to Repurpose Azithromycin for Use against Pseudomonas aeruginosa

A major contributor to fatalities in cystic fibrosis (CF) patients stems from infection with opportunistic bacterium Pseudomonas aeruginosa. As a result of the CF patient's vulnerability to bacterial infections, one of the main treatment focuses is antibiotic therapy. However, the highly adaptive nature of P. aeruginosa, in addition to the intrinsic resistance to many antibiotics exhibited by most Gram-negative bacteria, means that multi-drug-resistant (MDR) strains are increasingly prevalent. This makes the eradication of pseudomonal lung infections nearly impossible once the infection becomes chronic. New methods to treat pseudomonal infections are greatly needed in order to eradicate MDR bacteria found within the respiratory tract, and ultimately better the quality of life for CF patients. Herein, we describe a novel approach to combatting pseudomonal infections through the use of bis-2-aminoimidazole adjuvants that can potentiate the activity of a macrolide antibiotic commonly prescribed to CF patients as an anti-inflammatory agent. Our lead bis-2-AI exhibits a 1024-fold reduction in the minimum inhibitory concentration of azithromycin in vitro and displays activity in a Galleria mellonella model of infection.

NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES

The present invention relates to novel 5-substituted imidazolylmethyl derivatives, to processes for preparing these compounds, to compositions and mixtures comprising these compounds, and to the use thereof as biologically active compounds, especially for